Arbor Capital Management (Alaska)’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-4,594
Closed -$234K 110
2022
Q4
$234K Sell
4,594
-310
-6% -$14.9K 0.21% 91
2022
Q3
$217K Sell
4,904
-4,643
-49% -$226K 0.2% 93
2022
Q2
$501K Sell
9,547
-28,333
-75% -$1.44M 0.48% 70
2022
Q1
$1.94M Sell
37,880
-19,780
-34% -$1.03M 1.49% 22
2021
Q4
$3.4M Buy
+57,660
New +$2.86M 2.41% 4

Other funds holding PFE

Arbor Capital Management (Alaska)'s PFE Position: Q1 2023 in Review

Arbor Capital Management (Alaska) sold out of Pfizer (PFE) in Q1 2023, closing a stake of 4,594 shares — an estimated $234K sold.

Arbor Capital Management (Alaska) first reported a position in PFE in Q4 2021 and held it in 5 quarters. The position peaked at $3.4M in Q4 2021. 3,103 funds tracked by Wall St. Rank hold PFE as of Q1 2023.

  • Arbor Capital Management (Alaska) reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
  • Arbor Capital Management (Alaska) sold 4,594 Pfizer shares in Q1 2023, an estimated $234K.
  • Arbor Capital Management (Alaska) first reported a position in Pfizer in Q4 2021 and held it in 5 quarters.
  • Arbor Capital Management (Alaska)'s Pfizer position peaked at $3.4M in Q4 2021.
  • 3,103 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.

Based on Arbor Capital Management (Alaska)'s 13F filing for Q1 2023, filed 15 May 2023.